The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Rapcabtagene autoleucel in patients with R/R DLBCL
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, comments on the promising results of a new CAR T-cell product, rapcabtagene autoleucel, in treating relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) after two lines of therapy. Dr Barba reports an overall response rate of 88% and complete remission of 65% in 63 patients treated with the product, which was manufactured rapidly in under two days, and a favorable safety profile with a progression-free survival of 11.9 months. Dr Barba also notes that low-dose lymphodepleting chemotherapy was associated with fewer cases of severe CRS and better efficacy results, despite some differences in baseline characteristics This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
